GSK raises annual forecasts again on strong Arexvy launch

GSK raises annual forecasts again on strong Arexvy launch

Upworthy

Published

GSK raised its full-year profit and sales forecasts on Wednesday for the second time this year, betting on the strong launch of its respiratory syncytial virus (RSV) vaccine and steady demand for its shingles shot. Analysts expect GSK's RSV vaccine Arexvy to power future growth, stemming worries…

#gsk #rsv #arexvy #heartburndrug #zantac

Full Article